Research Reference
NAD+
Essential coenzyme — mitochondrial energy, DNA repair, sirtuin activation
Research & educational purposes only. BioMaxFit does not sell, promote, or represent peptides in any way. We are strictly educational and recommend working with your doctor on anything health-related. The information below comes from published research and documents what has been studied, not what should be done. Many of these compounds are investigational and not approved by the FDA; possession or use outside an authorized clinical trial may be illegal in your jurisdiction. This is not medical advice.
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every living cell, essential for mitochondrial energy production, DNA repair, and sirtuin activation. NAD+ levels decline approximately 50% between ages 40 and 60 (Massudi et al., 2012), driving interest in direct supplementation to restore youthful concentrations.
NAD+ is not FDA-approved as an anti-aging therapy. It is unique among peptides in having five practical administration routes, each with different onset and bioavailability: subcutaneous injection, IV infusion, sublingual, nasal spray, and oral precursors (NMN/NR).
Standard community protocol: 100 mg subcutaneous, 2–3 days per week.
Dosing Reference
Reconstitution
Add 5 mL bacteriostatic water to the 500 mg vial. Resulting concentration: 100 mg/mL.
| Dose | Syringe Units | mL Volume | Schedule |
|---|---|---|---|
| 50 mg | 50 units | 0.5 mL | 2–3x/week SubQStarter |
| 100 mg | 100 units | 1 mL | 2–3x/week SubQStandard |
| 200 mg | 200 units | 2 mL | 2x/week SubQAdvanced |
Math assumes U-100 insulin syringes (1 mL = 100 units). Verify your syringe matches before use. Round half-units to the nearest visible mark.
Reconstitution
For a 500 mg vial with 5 mL bacteriostatic water, the concentration is 100 mg/mL. A 100 mg dose draws to 100 units (1 mL) on a U-100 insulin syringe.
NAD+ is less stable in solution than many peptides, so prompt refrigeration matters. Refrigerate after mixing and use within 28 days.
Buffered vs unbuffered: Reconstituted NAD+ is acidic, and subcutaneous tissue registers that as burning; buffered (pH-adjusted) NAD+ is reported to inject far more comfortably than plain acidic stock. The trade-off is comfort only — the dose and its effect are unchanged.
Cycling Protocol
NAD+ doesn't require strict cycling like most peptides. The "as needed" approach reflects that NAD+ is a coenzyme, not a receptor agonist — there's no desensitization concern in the same way.
Community protocols most commonly describe an 8–12 week injectable course (100–200 mg SC 2–3x/week), with oral NMN (500 mg daily) as a bridge during off periods before repeating.
Routes of Administration
NAD+ is unique among peptides in having five practical administration routes:
| Route | Dose Range | Frequency | Onset | Bioavailability | | --- | --- | --- | --- | --- | | Subcutaneous injection | 100–200 mg | 2–3x per week | Days | High (direct) | | IV infusion | 250–500 mg | 1–2x per month | Hours | Highest | | Sublingual | 50–100 mg | Daily | 1–2 weeks | Moderate | | Nasal spray | 25–50 mg | Daily | 1–2 weeks | Moderate | | Oral NMN | 250–1000 mg | Daily | 2–4 weeks | Indirect | | Oral NR | 300–1000 mg | Daily | 2–4 weeks | Indirect |
Subcutaneous injection is the route community and clinical protocols most commonly use. Injection site stinging lasting 5–15 minutes is the most frequently reported side effect; community sources describe slow injection and site rotation.
Stacking Protocols
| Stack | Purpose | Protocol | | --- | --- | --- | | NAD+ + MOTS-c | Metabolic + energy substrate | NAD+ 100 mg 2–3x/week + MOTS-c 1 mg 5-on/2-off | | NAD+ + SS-31 | Mitochondrial optimization + fuel | NAD+ 100 mg 2–3x/week + SS-31 500 mcg 5-on/2-off | | NAD+ + Epitalon | Energy + telomere maintenance | NAD+ during off periods between Epitalon courses |
NAD+ is a coenzyme that complements receptor-acting peptides — it provides the fuel (NAD+) that sirtuins and mitochondrial enzymes need, while peptides like MOTS-c and SS-31 optimize the machinery that uses it.
Side Effects & Safety
- Injection site stinging — the most frequently reported side effect with subcutaneous injection, lasting 5–15 minutes; buffered NAD+ reduces this
- Nausea — occasional, particularly with IV infusion at higher doses
- Flushing or warmth — transient, more common with IV
- Headache — occasional
- Energy fluctuations — some users report initial energy changes in the first few days
- No serious adverse events reported in clinical trial settings at studied doses
NAD+ is not FDA-approved as an anti-aging therapy.
Research Basis
NAD+ levels decline approximately 50% between ages 40 and 60 (Massudi et al., 2012, PMID 22848760).
IV infusion (Grant et al., 2019, PMID 31164643): A single 3-hour infusion of 750 mg increased blood NAD+ approximately 398% above baseline. Loading protocols use 250–500 mg daily for 3–5 days.
Oral NMN (Yoshino et al., 2021, PMID 33888596): 250 mg/day for 12 weeks significantly increased NAD+ metabolites and improved physical performance.
Oral NR (Martens et al., 2018, PMID 29599478): 1000 mg/day increased whole-blood NAD+ by ~60% over 6 weeks.
NAD+ is a coenzyme, not a receptor agonist — there's no desensitization concern in the same way as peptide hormones.